ALX Oncology Q4 Earnings Call Highlights

ALX Oncology (NASDAQ:ALXO) outlined progress across its two core programs—CD47 blocker evorpacept and EGFR-targeted antibody-drug conjugate ALX2004—while providing updated clinical timelines and ...
CURE

Advances and Patient-Focused Research Highlight Day Two of ASCO GU

Overall, day two of ASCO GU emphasized that advances in therapy must go hand-in-hand with patient-centered research. These ...

Avacta's Precision Mechanism For Payload Delivery Shows Key Advantages Compared To An Antibody Drug Conjugate In Innovative AI-Driven Analysis

Avacta's Precision Mechanism For Payload Delivery Shows Key Advantages Compared To An Antibody Drug Conjugate In Innovative AI-Driven Analysis. Experimental data from FAP-Exd (AVA6103) demonstrates a ...

ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains ...

Promatix Biosciences Presents Positive Preclinical Data with First-in-Class PBS293 EGFR×EphA2 Cis-Bispecific ADC Demonstrating Enhanced Tumour Selectivity

Data presented at 16th World ADC London Summit with lead programme in colorectal cancer highlight the promise of Promatix’s proteomics-based ...
PharmiWeb

Kivu Bioscience Presents KIVU-305 Preclinical Data at World ADC London 2026 and Advances into Phase 1 Clinical Trial

Receives Australian HREC Approval and CTN Clearance for First-in-Human StudySAN MATEO, Calif.--(BUSINESS WIRE)--#ADC--Kivu Bioscience, Inc., a clinical-stage biotechnology company developing ...
Fierce Biotech

BioNTech advances DualityBio ADC into phase 3 with half the patients of Merck-Daiichi rival

BioNTech and partner DualityBio are accelerating the development of their B7-H3 antibody-drug conjugate into a phase 3 trial for metastatic castration-resistant prostate cancer (mCRPC). | BioNTech and ...

Creative Biolabs Elevates Antibody Post-Production Standards with Integrated Processing and Purification Solutions

Creative Biolabs announces upgraded downstream services designed to bridge the gap between raw antibody expression and ...

Helix BioPharma Corp. Announces Presentation at 16th Annual World ADC London

Helix BioPharma Corp. (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP0") ("Helix" or the "Company"), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers ...

Creative BioMart Introduces New Product Line to Advance Fc Receptor Research

As key molecules on the surface of immune cells, Fc receptors are the core hub of antibody-mediated effector functions. They play an irreplaceable role in physiological processes such as ...
The Manila Times

Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board

Dr. Anczukow is a leading cancer biologist with expertise in RNA biology, molecular and cell biology, as well as human genetics, cancer biology, and genomics ...

Avacta upbeat on preCISION comparative study

Avacta Therapeutics said on Tuesday that new preclinical analysis indicated its proprietary 'preCISION' tumour-activated delivery platform could offer pharmacokinetic advantages over the marketed ...